Who this is for
Manufacturers of higher-risk devices for which PMA may be the applicable pathway after specialist classification review.
Medical Devices
FDA PMA Evidence and Submission Planning
ConformArc handles the initial enquiry and helps connect you with a relevant provider for this requirement. The selected provider confirms applicability, technical scope, deliverables, fees and timing. The following explains work that may be relevant to the project; it is not a fixed package supplied by ConformArc.
Typical work to discuss with a provider
- Initial feasibility and pathway review
- Nonclinical/bench evidence mapping
- Clinical-evidence workstream coordination where applicable
- Manufacturing and QMS readiness planning
- Submission-project coordination
- Response/workstream tracking
Useful inputs for an initial review
- Device and indication
- Classification information
- Design history
- Preclinical and clinical evidence
- Manufacturing controls
- Risk analysis and prior FDA interactions.
Scope and report acceptance. PMA evidence planning requires verified senior regulatory and clinical capability. FDA alone decides an application.
Role clarity. Enquiry support and specialist introductions. Testing, technical advice, certification and regulatory decisions remain with the responsible service providers and authorities.
ConformArc handles the initial enquiry and helps connect you with a relevant provider for this requirement. The selected provider confirms applicability, technical scope, deliverables, fees and timing. The following explains work that may be relevant to the project; it is not a fixed package supplied by ConformArc.
Premarket approval (PMA) is a demanding FDA pathway for applicable devices. It is not interchangeable with 510(k) clearance or De Novo classification. ConformArc can coordinate a specialist feasibility and evidence review when the product’s classification and development stage warrant it.
The first work package should confirm the regulatory route and map nonclinical, clinical, manufacturing, quality-system and labelling evidence against current FDA expectations. Significant gaps may require a multi-stage programme and discussions with FDA through appropriate channels. The deliverable is a scoped development and submission plan with owners, dependencies and uncertainties, not a promise of approval. FDA alone decides an application.
Frequently asked questions
Is PMA a faster form of 510(k)?
No; the standards and evidence burden differ.
Sources / further reading
Requirements can change. Confirm the current route and applicable edition for the specific product before starting the project.
Discuss this requirement
Share your product details for FDA PMA Evidence and Submission Planning. The form lists this service and closely related options only.